Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS

Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS

Annual-Meeting

4 months
270 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS .
Up Next Autoplay
BEACON Trial: What's Next?
BEACON Trial: What's Next?
Category: Colorectal Cancer
2 Views
Cancer-News 3 days
Phase 3 BEACON CRC Trial
Phase 3 BEACON CRC Trial
Category: Colorectal Cancer
58 Views
Cancer-News 3 days
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...
Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic ...
Category: Colorectal Cancer
26 Views
Cancer-News 2 weeks
How does this affect treatment?
How does this affect treatment?
Category: Colorectal Cancer
8 Views
Cleveland Clinic 4 weeks
Is this truly safe?
Is this truly safe?
Category: Colorectal Cancer
1 Views
Cleveland Clinic 4 weeks
Radiation Therapy in Patients with Inflammatory Bowel Disease and Rectal Cancer
Radiation Therapy in Patients with Inflammatory Bowel Disease and Rectal Cancer
Category: Colorectal Cancer
10 Views
Cleveland Clinic 4 weeks
IDEA: Factors to consider
IDEA: Factors to consider
Category: Colorectal Cancer
2 Views
moasc 1 month
The impact the IDEA data will have on clinicians
The impact the IDEA data will have on clinicians
Category: Colorectal Cancer
1 Views
moasc 1 month
IDEA: 3 vs. 6 months
IDEA: 3 vs. 6 months
Category: Colorectal Cancer
1 Views
moasc 1 month
The IDEA Collaboration
The IDEA Collaboration
Category: Colorectal Cancer
4 Views
moasc 1 month